Tom John, Medical Oncologist and Translational Researcher at Peter MacCallum Cancer Centre, recently shared on X:
“Mal Itchins gave a stellar discussion of ARROS1 first line data.
Excellent comparison with other agents and ending with need for access the ros1 cancer and deserved the applause it received.”
You can also read:
WCLC 2026 Opens in Seoul: Targeted Therapy Moves Earlier as SCLC Enters a New Therapeutic Era
Other articles feauturing Tom John on OncoDaily.
